227 Patient Pre-Selection Outcomes for the European GENEGRAFT Ex Vivo Phase I/Ii Gene Therapy Trial for Recessive Dystrophic Epidermolysis Bullosa

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2017.07.224
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Safety and Early Efficacy Outcomes for Lentiviral Fibroblast Gene Therapy in Recessive Dystrophic Epidermolysis Bullosa

JCI insight
Medicine
2019English

Recessive Dystrophic Epidermolysis Bullosa Inversa

2020English

Translating the Combination of Gene Therapy and Tissue Engineering for Treating Recessive Dystrophic Epidermolysis Bullosa

2018English

Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa

New England Journal of Medicine
Medicine
2010English

Mesenchymal Stem Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa: Prospects and Clinical Progress

Expert Opinion on Orphan Drugs
ToxicologyPharmaceuticsPharmacologyHealth Policy
2016English

Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa Using a Self-Inactivating COL7A1 Retroviral Vector

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2016English

1021 Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients Harboring Nonsense Mutations

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Gene Therapy for Epidermolysis Bullosa

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Image Gallery: Multiple Localized Lipoatrophy in Recessive Dystrophic Epidermolysis Bullosa

British Journal of Dermatology
DermatologyMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy